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We compared passive surveillance and International 
Classiﬁ   cation of Diseases, 9th Revision, codes for com-
pleteness of staphylococcal toxic shock syndrome (TSS) 
surveillance in the Minneapolis–St. Paul area, Minnesota, 
USA. TSS-speciﬁ  c codes identiﬁ  ed 55% of cases compared 
with 30% by passive surveillance and were more sensitive 
(p = 0.0005, McNemar χ2 12.25).
S
taphylococcal toxic shock syndrome (TSS) is a severe 
illness associated with toxin-producing Staphylococcus 
aureus. First named in 1978, TSS has been associated with 
tampon use, intravaginal contraceptive devices, and skin 
infections, particularly after surgical procedures (1,2). In 
January 1980, the Minnesota Department of Health (MDH) 
initiated surveillance for TSS with active and passive com-
ponents. The national incidence of TSS decreased during 
1980–1996 (3,4) after removal of high-absorbency tam-
pons from the market and public awareness campaigns. In 
subsequent years, surveillance methods in Minnesota were 
changed to a solely passive surveillance system that relied 
on clinicians to report cases. MDH uses the 1997 case deﬁ  -
nition of the Centers for Disease Control and Prevention 
(CDC) (Atlanta, GA, USA) to determine case criteria for 
any probable TSS case (>4 clinical criteria and laborato-
ry criteria) considered reportable (Table 1) (5). Given the 
complexity of the case deﬁ  nition, we suspected that TSS 
underreporting was likely.
Recently, several factors, including increasing preva-
lence of community-associated methicillin-resistant S. 
aureus that carries superantigens and the trend toward 
earlier menarche, suggested that the incidence of TSS 
might be increasing (6,7). Additionally, the number of 
requests for superantigen testing in the Minneapolis–St. 
Paul (MSP) area made to a reference microbiology labo-
ratory that tests staphylococcal isolates from TSS cases 
increased during 2000–2003 (8). To determine the inci-
dence of TSS, active surveillance was initiated at all MSP 
area hospitals using International Classiﬁ  cation of Dis-
eases, 9th Revision (ICD-9), codes assigned at hospital 
discharge. We compared passive surveillance reports with 
ICD-9 codes to determine an effective and efﬁ  cient sur-
veillance method for TSS.
The Study
The MSP area is composed of 7 counties with a popu-
lation of 2,642,056 (2000 US Census) and 24 acute-care 
hospitals. Requests were sent to medical record depart-
ments of these hospitals for data on inpatients discharged 
from hospitals from January 1, 2000, through December 
31, 2003, whose medical records indicated >1 of the select 
ICD-9 study codes. Medical records from all hospitaliza-
tions receiving the TSS-speciﬁ  c code (040.82 or 040.89) 
were reviewed (Figure), and a 20% random sample of 
medical records from hospitalizations that received >1 
nonspeciﬁ  c TSS study code (Table 2) from within each 
hospital was reviewed. Each medical record was reviewed 
for TSS case criteria and pertinent epidemiologic and clini-
cal information. Additionally, death certiﬁ  cates assigned 
the ICD-10 code for TSS (A48.3) and cases from the Min-
nesota Unexplained Critical Illness and Death of Possible 
Infectious Etiology project (UNEX) (9) during 2000–2003 
were reviewed. TSS cases identiﬁ  ed through ICD-9 code 
searches were compared with cases reported to MDH dur-
ing 2000–2003. Data were analyzed with Stata version 9 
(StataCorp, College Station, TX, USA). Statistical analyses 
included Pearson and McNemar χ2 tests.
Of 7,414 hospitalizations with >1 study code, 116 
(1.6%) were assigned the TSS-speciﬁ  c code and were re-
viewed (Figure). Of the remaining 7,298 hospitalizations 
assigned >1 nonspeciﬁ  c TSS code, 1,575 (21.6%) random-
ly selected hospitalizations were reviewed. Of these 1,691 
hospitalizations, 55 had 5 or 6 criteria for TSS, of which 12 
(22%) met the CDC case deﬁ  nition for streptococcal TSS, 
and 7 were non-MSP residents. The remaining 36 cases 
were probable or conﬁ  rmed TSS. No cases from UNEX 
or death certiﬁ  cate searches met the TSS case deﬁ  nition. 
Of the 36 TSS cases, 17 (47%) were reported to MDH by 
passive surveillance. Thirty-one (86%) cases were found 
by using TSS-speciﬁ  c ICD-9 codes. Five cases were found 
by using non-TSS–speciﬁ  c ICD-9 codes. After adjusting 
for 20% random sampling for cases identiﬁ  ed by non-TSS–
speciﬁ  c codes, we identiﬁ  ed the estimated number of cases 
by using non-TSS–speciﬁ  c codes to be 25. This analysis 
resulted in 56 estimated TSS cases identiﬁ  ed in the surveil-
lance area during 2000–2003 by using ICD-9 codes.
The TSS-speciﬁ  c ICD-9 code search identiﬁ  ed 31 of 
the 56 estimated TSS cases (sensitivity 55%, speciﬁ  city 
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surveillance (sensitivity 30%, speciﬁ  city 99.9%); all were 
coded with the TSS-speciﬁ  c code. The TSS-speciﬁ  c ICD-9 
code search was more sensitive than passive surveillance (p 
= 0.0005, McNemar χ2 12.25). Of those cases reported to 
MDH, more were likely to be associated with menstruation 
(14/17 vs. 5/19; p<0.001) and to have had a positive test re-
sult for S. aureus (16/17 vs. 11/19; p = 0.01). Twenty-seven 
of 36 TSS cases detected had a bacterial culture positive 
for S. aureus. The 3 TSS cases with methicillin-resistant 
S. aureus isolates were not reported to MDH. The posi-
tive predictive value of being a case among those coded 
with the TSS-speciﬁ  c code was 27% (31/116). In 68 of 116 
cases that received the TSS-speciﬁ  c code, there was clini-
cal suspicion of TSS, but these cases did not meet the clini-
cal case deﬁ  nition (<5 criteria): 10 were streptococcal TSS 
and 7 were in non-MSP residents. All 17 cases reported to 
MDH were detected through the ICD-9 code search.
Conclusions
Surveillance for TSS is challenging given the lack 
of a diagnostic test and a case deﬁ  nition with multiple 
components. Under the current passive surveillance sys-
tem, between one third and half of potential TSS cases 
were identiﬁ  ed. Discrepancies were found in reporting, 
with menstruation-associated cases more likely to be re-
ported to MDH than nonmenstrual-associated cases. This 
discrepancy was observed with prior active surveillance 
efforts (10).
Using ICD-9 codes, we found 12 TSS cases that were 
of streptococcal etiology. Accuracy may be improved by 
developing separate ICD-9 codes speciﬁ  c for staphylococ-
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Figure. Flow diagram of toxic shock syndrome (TSS) case 
ascertainment. TSS cases were identiﬁ   ed from International 
Classiﬁ  cation of Diseases, 9th Revision (ICD-9), codes assigned at 
hospital discharge, cases reported to the Minnesota Unexplained 
Critical Illness and Death of Possible Infectious Etiology project 
(UNEX), and death certiﬁ   cate data by using International 
Classiﬁ   cation of Diseases, 10th Revision (ICD-10), code A48.3. 
MSP, Minneapolis–St. Paul area.
Table 1. Staphylococcal toxic shock syndrome case definitions* 
Criteria Definition
Clinical
 Fever    Temperature  >38.9°C (102.0°F) 
  Rash  Diffuse macular erythroderma 
  Desquamation  1–2 weeks after onset of illness, particularly on the palms and soles 
  Hypotension  Systolic blood pressure <90 mm Hg for adults or <5th percentile by age for children <16 years of 
age; orthostatic decrease in diastloc blood pressure >5 mm Hg from lying to sitting, orthostatic 
syncope, or orthostatic dizziness 
  Multisystem organ involvement† 
    Gastrointestinal  Vomiting or diarrhea at onset of illness 
    Muscular  Severe myalgia or creatine phosphokinase level at least twice the upper limit of normal 
    Mucous membrane  Vaginal, oropharyngeal, or conjunctival hyperemia 
    Renal  Blood urea nitrogen or creatinine at least twice the upper limit of normal for laboratory or urinary 
sediment with pyuria (>5 leukocytes by high-power field) in the absence of urinary tract infection 
    Hepatic  Total bilirubin, alanine aminotransferase, or aspartate aminotransferase levels at least twice the 
upper limit of normal 
  Hematologic  Platelet  counts  <100 × 10
9/L
    Central nervous system  Disorientation or alterations in consciousness with focal neurologic signs when fever and 
hypotension are absent 
Laboratory 
  Culture  If obtained, negative results on blood, throat, or cerebrospinal fluid cultures (blood culture may 
be positive for Staphylococcus aureus)
  Titer  If obtained, no increase in titer for Rocky Mountain spotted fever, leptospirosis, or measles 
Case classification 
  Probable  Meets laboratory criteria and in which 4 of 5 clinical findings described above are present 
  Confirmed  Meets laboratory criteria and in which all 5 of the clinical findings described above are present, 
including desquamation, unless the patient dies before desquamation occurs 
*From the US Centers for Disease Control and Prevention (5). 
†Involving >3 organ systems. cal, streptococcal, or unidentiﬁ  ed TSS. In addition to the 
TSS-speciﬁ  c ICD-9 code, we selected 5 other ICD-9 codes 
on the basis of previous studies to address the concern that 
TSS cases may be classiﬁ  ed under a staphylococcal infec-
tion or sepsis code, but not the TSS-speciﬁ  c code (8–10). 
These 5 additional non-TSS–speciﬁ  c ICD-9 codes required 
reviewing 1,575 medical records; only 5 (0.3%) additional 
TSS cases were identiﬁ  ed. The non-TSS–speciﬁ  c ICD-9 
codes detected 25 estimated cases. However, this detection 
required 8 trained staff and substantial resources with ≈40 
minutes required per medical record review.
Passive surveillance requires fewer public health re-
sources because it relies on clinicians to report cases. Ac-
tive surveillance involves public health resources in identi-
fying cases. The disadvantage of passive surveillance is the 
potential for missed cases. Despite possible inaccuracies 
associated with the assignment of ICD-9 codes, these codes 
represent a standardized data source that may be readily 
available. In the absence of a speciﬁ  c diagnostic test, ICD-9 
codes represent an efﬁ  cient method for surveillance and 
following trends.
Medical record abstraction per hospitalization was 
labor- and resource-intensive and is not feasible for most 
health departments. With increasing use of automated elec-
tronic reporting for disease surveillance (11), querying 
hospital discharge data for the TSS-speciﬁ  c ICD-9 code 
is a feasible adjunct to passive surveillance to detect TSS 
trends over time. Consequently, it is imperative that clini-
cians and coders are thorough to ensure that ICD-9 codes 
are accurate.
We found it useful to add regular ICD-9 code searches 
for TSS-speciﬁ  c codes as an active surveillance adjunct to 
our passive surveillance system. This addition increases 
sensitivity of TSS surveillance with a minimal increase 
in resources. Use of this more sensitive system increases 
the ability to detect trends in TSS, which may develop be-
cause of changes in bacterial virulence characteristics, host 
characteristics such as the use of new devices or products, 
changes in human behavior, or changes in host suscepti-
bility. Evaluation of this approach in other areas to assess 
sensitivity of TSS surveillance would be useful because 
coding practices may differ.
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